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Abstract
Background: The dominant risk factor for urinary bladder cancer has been cigarette smoking, but, as smoking
prevalence is decreasing in many populations, other risk factors may become uncovered. Such new risk factors
could be responsible for halting the declining incidence of bladder cancer. We hypothesize that snuff use by
Swedish men may increase the rate for bladder cancer, as snuff contains carcinogenic nitrosamines.
Methods: We carried out an ecological study by comparing incidence trends in lung and bladder cancers between
Danish, Finnish and Swedish men in order to test if the Swedish bladder cancer rate deviates from the Danish and
Finnish ones. We used the NORDCAN database for cancer data from 1960 through 2016 to test the hypothesis.
Results: In the three countries, the incidence of lung cancer started to decrease after a peak incidence, and this
was later followed by declining incidence in bladder cancer in Denmark from 1990 to 2016 by 14.3%, in Finland by
8.3% but not in Sweden (the decline of 1.4% was not significant). The difference in trends can be partly explained
by the increasing incidence in Swedish men aged 70 or more years. Sweden differs from the two other countries
by low male smoking prevalence but increasing use of snuff recorded by various surveys.
Conclusion: The stable bladder cancer trend for Swedish men was opposite to the declining trends in Denmark,
Finland and globally. We suggest that this unusual finding may be related to the increasing use of snuff by Swedish
men. Average users of snuff are exposed to at least 3 times higher levels of carcinogenic tobacco-specific
nitrosamines than a smoker of one daily pack of cigarettes.
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Introduction
The incidence trends of lung and urinary bladder can-
cers have marked the cigarette smoking epidemic which
started in various countries before or after World War II
[1, 2]. The incidence rates followed the consumption of
cigarettes with a lag time of 20 to 40 years and have
started to decline as the number of smokers has dimin-
ished [3, 4]. Relative risks for tobacco-related lung can-
cer are of the order of 10 to 20 in active smokers
compared to non-smokers, depending on pack-years
smoked and other factors, and they remain at levels of
3–5 after 20 years of quitting [5, 6]. Risk of bladder can-
cer is about 2–4 times higher for active smokers [5, 7–
10]. In former smokers the risk is around 2 fold higher,
depending on the time since quitting, and it may take at
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least 30 years to reach the incidence level of non-
smokers [5, 7–9]. The changing composition of ciga-
rettes and tobacco have apparently lowered the risk of
lung cancer by about 20% but increased the risk of blad-
der cancer by 30% [11, 12]. Other risk factors for these
cancers include occupational exposures, air pollution,
type 2 diabetes and family history [10, 13–16]. As the
proportion of smokers decreases, it is likely that cancer
trends at smoking related sites will be influenced by
weaker risk factors prevalent in the population.
A unique aspect of smoking habits among Swedish
men is that their smoking prevalence decreased earlier
than in other European countries, resulting in the lowest
lung cancer incidence at least since 1980 [17, 18]. Lung
cancer rates for Danish and Finnish men decreased
slower but, in contrast to Swedish men, they did not
take up the habit of oral tobacco (snuff, locally called
‘snus’) use. The use of snuff increased in Sweden anti-
parallel to smoking and in the early 1990s daily snuff
users (20%) passed daily smokers in prevalence [19]. Sev-
eral studies have examined possible carcinogenic effects
of the Swedish snuff. Recent studies reported a small
overall excess mortality in cancer and risk of rectal but
not of colon cancer [20, 21]. Studies on oral and pancre-
atic cancers have been negative [22, 23]. US users of
smokeless tobacco have an increased risk of oral and
bladder cancers [24].
We carried out an ecological study by comparing the
incidence change between lung and bladder cancers be-
tween Danish, Finnish and Swedish men in order to test
if the Swedish bladder cancer trend deviates from the
Danish and Finnish ones, hypothesizing that snuff use
may increase the rate for bladder cancer. We used the
NORDCAN database, originating from the local cancer
registries, to test the hypothesis.
Materials and methods
Tobacco use by Danish, Finnish and Swedish men
The three Nordic countries (Denmark, Finland and
Sweden) have quite different past patterns of smoking,
including among the highest male smoking prevalence
in Europe for Denmark and Finland, and the lowest
prevalence in Sweden (www.pnlee.co.uk/ISS.htm) [25,
26]. World War II boosted smoking among Finnish
men, as each solder was entitled to a daily ration of 5
cigarettes; the habit continued and smoking prevalence
among Finnish men remained at 60% until 1960. Yet the
prevalence was lower than for Danish men and some-
what higher than for Swedish men (www.pnlee.co.uk/
ISS.htm) [27, 28]. Subsequently, smoking prevalence de-
clined fastest for Swedish and slowest for Danish men
[17]. Of particular interest in this comparison is the vari-
able use of oral tobacco (snuff/snus) by men in these
countries. While Swedish men reduced their smoking
level from 28% (daily smokers) in 1988/89 to 15% in
2004/05, daily snuff users increased from 19 to 27% in
the same period [19]. More than half of daily snuff users
were non-smokers. The highest prevalence of snuff users
(rather stable at 30%) was in men aged 20 to 29, and
among older men snuff use increased steadily. Among
Finnish men, 36% were daily smokers in 1988/89, which
deceased to 28% in 2004/05 [19]. Daily consumption of
snuff was recorded only for 2004/05 at 3%. Snuff use has
also been low in Denmark.
Data analysis
We used the NORDCAN database which is a compil-
ation of data from the high-level Nordic cancer registries
as described [29] (https://NORDCAN.iarc.fr/en/
database#bloc2). In the database, bladder cancer is part
of urothelial cancers covered by the codes C65–68 (can-
cers of the pelvis, ureter, bladder), D09.0–1, D30.1–9,
D41.1–9 (in situ and tumors of undefined behavior at
these sites). Coding practices for bladder cancer have
been internationally variable as far as consideration of
benign lesions. In NORDCAN these lesions were in-
cluded retroactively in 2015; however it is unclear how
uniform the classification of benign lesions was back in
time [30]. Nevertheless, the historic incidence data for
bladder cancer show no abrupt changes over time.
The vast majority of urothelial cancers are located in
the bladder (90–95% of all) with the upper urinary tract
(renal pelvis and ureter) accounting for the rest [31]. For
simplicity and the dominance of a single entity, we call
these cancers as ‘bladder cancer’. Urothelial cancers
share risk factors, including smoking [5, 31, 32].
For incidence analysis, the world standard population
was used in age adjustment. In incidence diagrams 3-
year smoothing was used because of small case numbers;
in smoothing, moving averages are calculated for each
data point over 3 years. In assessing incidence trends es-
timated annual percentage change (EAPC) was used to
describe the magnitude of change in the trend on fitting
a regression model (shown in some figures as a dotted
line) to the log of the age standardized incidence rate.
This described the average annual rate change (%) over
the time period selected.
Results
Age-standardized incidence rates for lung and bladder
cancers in Nordic males are shown in Fig. 1. The highest
incidence in lung cancer was recorded for Finland,
reaching a maximum around 1970. The Danish and
Swedish incidence peaked in the early 1980s. The rates
for bladder cancer deviated from those of lung cancer.
Increasing incidences were noted in the three countries
until the 1990s; the Finnish rates remained the lowest
and the Danish rates the highest throughout the
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observation period. While the incidence of lung cancer
was much higher than that of bladder cancer, the rate
differences declined over the course of time, being 2 fold
in Finland and 1.5 fold in Denmark in the 2010s, when
the Swedish bladder cancer incidence surpassed that of
lung cancer.
Age-group specific analysis for male bladder cancer in
Denmark, Sweden and Finland is shown in Fig. 2. The
difference is seen in the two oldest age-group for which
the increase towards 2016 is steep in Sweden while in
Denmark and Finland a maximum in these age-groups is
reached in the 1990s. The Danish rates in the oldest
age-groups showed large rate fluctuations. In the bottom
of the panels we show the estimates for the prevalence
of snuff users (%) in the three countries.
In Table 1 we analyzed the estimated annual percent
change (EAPC) in bladder cancer among Nordic men
between 1995 (when the rates for Denmark and Finland
peaked) and 2016. In age-groups 60 to 85+ years, the
EAPCs for Denmark, Finland and Sweden were − 0.75, −
0.32 and 0.44%, respectively. The EAPC for Sweden was
significantly different from that of Denmark and Finland
(i.e., 95%CIs were non-overlapping). The increase in the
EAPC for Sweden was steepest in the oldest age-group
(1.42); this was significantly higher than the rates for
Denmark and Finland.
Some international studies compare bladder cancer
rates between years 1990 and 2016, and we calculated
EAPCs for these years (Table 2). The percent changes
were for Denmark − 0.84 [− 1.03;-0.66], for Finland −
0.49 [− 0.71;-0.26] and for Sweden − 0.08 [− 0.25;0.08]
[33]. The Swedish rate was close to 0 and not significant,
in contrast to significantly declining rates for Denmark
and Finland. These results calculated for period 1990 to
2016 from the EAPCs, were 14.3% for Denmark, 8.3%
for Finland and 1.4% for Sweden (not significant).
Age-specific incidence data for bladder cancer are
plotted at 10-year intervals (except for 2016) for Nordic
males in Supplementary Fig. 1. The contrast in these
graphs is largest for Finland (B) and Sweden (C); for
Fig. 1 Age-standardized incidence rates for Danish, Finnish and Swedish male lung and bladder cancer between 1960 and 2016. Lung cancer
curves for Danish, Finnish and Swedish men are shown by DL, FL and SL, respectively, and for bladder cancers accordingly DB, FB and SB
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Finland, the curves cluster together from year 1980 on-
wards, while for Sweden the rates increase in every 10-
year period for age-groups 80 years and higher. The Da-
nish rates for year 2000 and later showed no increase in
the oldest age-groups.
Discussion
The results showed that the incidence of bladder cancer
has not decreased in Swedish men after 1990, as it has
in Danish and Finnish men. This is in contrast to the
Swedish male lung cancer rate which turned into decline
after the early 1980s, and to the estimated population
frequency of smoking men, declining from 30.3% (1980)
to 11.1% (2006) [17]. This is also in contrast to the glo-
bal trends of decline in male bladder cancer incidence,
Fig. 2 Age-specific incidence rates for bladder cancer in Danish A, Swedish B and Finnish C men from 1980 through 2016. The dotted line shows
a regression line fitted to the log of the rate. Note that the y-axis scale for Denmark extend to 450/100,000 compared to Sweden and Finland of
350/100,000. In the bottom of each panel an estimate for the prevalence of snuff users is given as % of the population. The data for Sweden for
time points 1988/9, 1996/7 and 2004/5, and the 2004/5 for Finland were obtained from [19]; all other estimates were
from (www.pnlee.co.uk/ISS.htm)
Table 1 Case numbers and estimated annual percent change
(EAPC) in incidence in age groups of male bladder cancer in
Denmark, Finland and Sweden between 1995 and 2016
Country Cases EAPC [95%CI]
Age (years)
Denmark
60–85+ 25,992 − 0.75 [− 1.03;-0.47]
60–69 8643 −1.11 [− 1.58;-0.64]
70–79 11,073 − 0.73 [− 1.07;-0.38]
80–85+ 6276 0.16 [− 0.24;0.55]
Finland
60–85+ 14,208 − 0.32 [− 0.64;-0.01]
60–69 4157 − 0.17 [− 0.66; 0.34]
70–79 5914 −0.72 [− 1.28;-0.16]
80–89 4137 0.12 [− 0.32; 0.56]
Sweden
60–85+ 34,714 0.44 [0.22; 0.67]
60–69 9862 −0.07 [− 0.42; 0.28]
70–79 4494 0.57 [0.31; 0.82]
80–85+ 10,358 1.42 [1.09; 1.74]
95%CI = 95% confidence interval
Table 2 Case numbers and estimated annual percent change
(EAPC) in incidence of male bladder cancer in the three Nordic
countries between 1990 and 2016
Country Cases EAPC [95%CI]
Denmark 37,346 −0.84 [− 1.03;-0.66]
Finland 19,493 −0.49 [− 0.71;-0.26]
Sweden 47,534 −0.08 [− 0.25; 0.08]
95%CI = 95% confidence interval
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which between 1990 and 2016 were reported at 5.9%
[33]. The decline has been 11.5% for highly developed
countries, including Western Europe 13.9% and North
America 6.5%. Our results for Denmark and Finland,
calculated for the same period from the EAPCs, were
14.3% and 8.3%; the Swedish decline of 1.4% was not
significant.
Why would the trend for the male Swedish bladder
cancer differ from rates in the neighboring countries or
from global development? A change in diagnostic or
reporting practice may influence incidence rates, but no
such change is known. A comparison to female rates is
not helpful because Nordic women started to decrease
their smoking habits later than men, and female lung
and bladder cancer rates have been increasing until re-
cently according to the NORDCAN data. Because of the
low level of smoking among Swedish men, it is evident
that the population attributable fraction of smoking for
bladder cancer is declining, and other factors may exert
a detectable role. Considering the lag time between
smoking and bladder cancer of 20 to 40 years, smoking
related bladder cancer should still be declining in Swed-
ish men [3, 4]. Thus, new factor(s) appear to counteract
this decline. We cannot find any more plausible explana-
tions than the increasingly wide use of snuff by Swedish
men.
Snuffing is a historical habit in Sweden but the habit
decreased in popularity against cigarette smoking [34].
The amount of sold snuff reached the lowest level in the
late 1960s but increased again and almost tripled by
2006. The habit was picked up fastest by young men and
by 1988/89 29% of men aged 20 to 30 years were snuff
users [19]. Swedish snuff is sold in two forms, poaches
(small packages) and in loose form; these have been con-
sumed in roughly equal proportions [34]. The average
daily consumption in Sweden has been estimated at ei-
ther 12 g of poached product or 30 g of loose product.
Tobacco-specific nitrosamines (TSNAs), N-
nitrosonornicotine (NNN) and 4-(methylnitrosamino)-1-
(3-pyridyl)-1-butanone (NNK) have been measured in
recent (since 2016) Swedish snuff products at the level
of 0.5 microgram/g [35]. Thus, a daily consumer of loose
snuff will ingest 15 micrograms/day after 2016, but
ingested higher amounts earlier [35]. For comparison,
TSNAs from a pack of low-tar cigarettes causes an ex-
posure of 5 micrograms [36]. Thus, an average loose
snuff user is currently exposed to 3 times higher levels
to TSNAs than a pack-a-day smoker, and the difference
was higher earlier [35]. TSNAs together with polycyclic
aromatic hydrocarbons (constituents in tar) are assumed
to be the most important carcinogens in tobacco smoke
[37]. While the development of low-tar cigarettes re-
duced one carcinogenic component, it increased TSNA
exposure [37].
Our age-group specific analysis showed that the in-
crease in the Swedish bladder cancer incidence took
place in the two oldest age groups, most steeply in the
80+ group (Fig. 2B). Those who were diagnosed in 2010
at the age of 80 were born in 1930. They belonged to
the heavy smoking birth cohort, which however smoked
less than their Danish and Finnish counterparts. Danes
and Finns were able to turn down the increasing trend
of bladder cancer for 70 to 79 year olds in contrast to
Swedes whose incidence increased (Fig. 2A, C).
Based on published epidemiological studies, where
snuff use has been assessed, the carcinogenic effects ap-
pear to be weak at best for the tumor types analyzed
[20–23]. These studies have been conducted well and
they include an individual assessment of snuff use,
which however was usually available at the baseline
only. The current snuffing habit is relatively new, after
sales started to increase in the late 1960s (www.pnlee.
co.uk/ISS.htm). According to sparse data from the lat-
ter source, consumers between 1970 and 1983
amounted to 13–16% of the male population. As the
habit started among relatively young men (29% users
among 20 to 29 year old in 1988/89) this cohort has
reached age 40 to 49 by years 2008/09 [19]. It is true
that even older men started with snuff but as the male
median age for cancer in Sweden is over 70 years, it
would be early to observe effects caused by an exposure
confined to a fraction of the population [38]. While the
generation of snuff users who never smoked is growing
older, current epidemiological approaches may try and
assess the possible interactions of dual use of cigarettes
and snuff [39].
The limitation of the study is its ecological approach,
as we have no information about individual snuff use.
The implication is that we can only speculate about the
causes of the observed trend changes. The strengths are
the access to high quality national data sources and thus
observation of trends in the entire population.
In conclusion, we observed an unexpected stabilization
of Swedish male bladder cancer incidence after 1990, be-
cause it disagreed with the decreasing smoking preva-
lence and lung cancer rate among Swedish men. The
stable bladder cancer trend was in contrast to declining
trends in Denmark, Finland, Western Europe, North
America and in the entire world. We suggest that this
unique phenomenon may be related to increasing use of
snuff by Swedish men. Average users of loose snuff in-
gest now 3 times more carcinogenic TSNAs than is in-
haled by a smoker of one daily pack of cigarettes, and
the difference was higher earlier before the reduction of
the TSNA content in snuff. At the population level, snuff
use in Sweden is relatively recent and the carcinogenic
effects, if true, will become more evident in years to
come.
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Additional file 1 Supplementary Fig. 1. Age-specific incidence data
for bladder cancer plotted in 10-year intervals from 1960 onwards (except
for 2016) for Danish (A), Finnish (B) and Swedish (C) males. The scale for
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